The landscape for developing new antibiotics is precarious, posing scientific and financial obstacles for drug companies. The formula involving the difficulty finding novel mechanisms to combat bacterial pathogens plus clinical trials and regulatory approval process and then provider delays in actually using new antibiotics, equals extremely expensive, complex and risk-prone conditions for new antibiotic development.
University of Wisconsin conducted a study to determine exactly how long providers (e.g. hospitals, health systems, etc.) are delaying the use of new antibiotic drugs, reported University of Minnesota’s CIDRP news.
Published in Diagnostic Microbiology and Infectious Disease, the Wisconsin team found that providers on average wait more than one year prior to prescribing any of the new six antibiotics approved by the FDA within the past five years.
The UW team examined a clinical administrative database of US medical centers from 2014 through 2018 to determine the first use of six new antimicrobials that had received qualified infectious disease product (QIDP) designation from the FDA—they included:
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).